314 related articles for article (PubMed ID: 32833533)
1. Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
Fry LE; Peddle CF; Stevanovic M; Barnard AR; McClements ME; MacLaren RE
CRISPR J; 2020 Aug; 3(4):276-283. PubMed ID: 32833533
[TBL] [Abstract][Full Text] [Related]
2. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
4. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
5. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing.
Lu B; Javidi-Parsijani P; Makani V; Mehraein-Ghomi F; Sarhan WM; Sun D; Yoo KW; Atala ZP; Lyu P; Atala A
Nucleic Acids Res; 2019 May; 47(8):e44. PubMed ID: 30759231
[TBL] [Abstract][Full Text] [Related]
6. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
8. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
9. Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors.
Fakhiri J; Nickl M; Grimm D
Methods Mol Biol; 2019; 1961():111-126. PubMed ID: 30912043
[TBL] [Abstract][Full Text] [Related]
10. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
13. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
Hiranniramol K; Chen Y; Wang X
Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
[TBL] [Abstract][Full Text] [Related]
15. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.
Kurata M; Wolf NK; Lahr WS; Weg MT; Kluesner MG; Lee S; Hui K; Shiraiwa M; Webber BR; Moriarity BS
PLoS One; 2018; 13(9):e0198714. PubMed ID: 30222773
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-gRNA Design.
Pallarès Masmitjà M; Knödlseder N; Güell M
Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
19. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
20. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
